Insulin Degludec Starting Dose and Titration
For insulin-naïve adults with type 2 diabetes, start insulin degludec at 10 units once daily, then titrate by 2 units every 3-4 days based on fasting plasma glucose until reaching target (typically 80-130 mg/dL). 1
Starting Dose
Type 2 Diabetes (Insulin-Naïve)
- Standard starting dose: 10 units once daily 1
- Alternative weight-based approach: 0.1-0.2 units/kg/day 2, 3
- Lower starting doses (consider 0.1 units/kg/day) for:
Type 1 Diabetes (Insulin-Naïve)
- Start at approximately one-third to one-half of total daily insulin dose
- Total daily insulin calculation: 0.2-0.4 units/kg body weight
- Remainder given as short-acting insulin divided among meals 1
Important distinction: The FDA label 1 provides the most authoritative dosing, specifying 10 units for type 2 diabetes regardless of weight, which differs from the weight-based approaches in some guidelines 2. The 10-unit fixed dose is simpler and safer for most patients.
Titration Schedule
Standard Titration Protocol
Increase by 2 units every 3-4 days until fasting plasma glucose reaches target 2, 1
- Target fasting glucose: 80-130 mg/dL (4.4-7.2 mmol/L) 3, 4
- Requires minimum 3 pre-breakfast glucose measurements per week 4
- Critical timing note: Degludec requires slower titration (≥3 days between adjustments) due to longer time to steady state compared to other basal insulins 2
Alternative Titration Approaches
Adjustable regimen (based on fasting blood glucose) 2:
- FBG >180 mg/dL: add 20% of current dose
- FBG 140-180 mg/dL: add 10% of current dose
- FBG 110-139 mg/dL: add 1 unit
For hypoglycemia 2:
- BG <70 mg/dL: reduce dose by 10-20%
- BG <40 mg/dL: reduce dose by 20-40%
Practical Titration Considerations
The ONWARDS trials used ±20 unit weekly adjustments based on 2 days prior plus day-of measurements 4. However, this aggressive approach may not be appropriate for all patients—more conservative 10-unit increments are reasonable once stable dose established, particularly in elderly or hypoglycemia-prone patients 4.
App-based titration tools can support dose adjustments, with higher adherence associated with better glucose control and lower hypoglycemia rates 4.
Switching from Other Basal Insulins
Adults
- Start degludec at same unit dose as total daily long/intermediate-acting insulin 1
- No dose conversion needed
Pediatric Patients (≥1 year)
- Start at 80% of total daily long/intermediate-acting insulin dose to minimize hypoglycemia risk 1
For faster glycemic control when switching: Consider one-time 50% loading dose for first injection (multiply daily basal dose by 10.5, rounded to nearest 10 units), then return to calculated weekly dose (daily dose × 7) from week 2 onward 4. This approach may be omitted if patient frequently misses doses, as this could lead to overestimation of actual insulin need 4.
Administration Details
- Timing flexibility: Adults can inject at any time of day (does not need to be same time daily); pediatric patients should inject at same time daily 1
- Minimum interval between doses: 8 hours 1
- Subcutaneous injection into thigh, upper arm, or abdomen
- Rotate injection sites to prevent lipodystrophy 1
- Never mix or dilute with other insulins 1
Common Pitfalls
- Inadequate initial dosing: Studies show initial doses are often too conservative and not individualized 5
- Too-rapid titration: Degludec's 25-hour half-life means steady state takes 2-4 weeks—wait ≥3 days between adjustments 2, 6
- Overbasalization: If dose exceeds 0.5 units/kg/day without achieving target, consider adding prandial insulin or GLP-1 RA rather than continuing to escalate basal dose 2, 3
- Dosing errors when switching: Forgetting to remove the one-time 50% loading dose after first injection can cause hypoglycemia 4